Lb Pharmaceuticals (LBRX) Cash from Financing Activities (2025 - 2026)
Lb Pharmaceuticals (LBRX) recorded quarterly Cash from Financing Activities of $93.8 million in Q1 2026, up 8119.74% quarter-over-quarter from -$1.2 million in Q4 2025.
Lb Pharmaceuticals (LBRX) Cash from Financing Activities (2025 - 2026) Analysis & Trends
Lb Pharmaceuticals' Cash from Financing Activities history runs 2 years deep, the most recent figure standing at $93.8 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $93.8 million; the TTM figure through Mar 2026 stood at $92.7 million (changed N/A YoY), while the FY2025 annual figure was $302.6 million, up 689.67% from the prior year.
- Cash from Financing Activities was $93.8 million for Q1 2026 at Lb Pharmaceuticals, up from -$1.2 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $93.8 million in Q1 2026 to a low of -$1.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Lb Pharmaceuticals | 843.30 Mn | 843.30 Mn | - | 93.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93.83 Mn |
| Mar 31, 2026 | 93.83 Mn |
| Dec 31, 2025 | -1.17 Mn |
| Dec 31, 2025 | -1.17 Mn |